GLP-1 Medications for Knee Osteoarthritis: STEP 9 and the Pain Question

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• STEP 9 trial showed semaglutide 2.4 mg reduced knee OA pain and improved function in adults with obesity and moderate-to-severe knee OA
• The mechanism is dominantly weight-mediated; for every pound lost, knee joint forces during walking decrease approximately 4 pounds
• No GLP-1 medication is FDA-approved specifically for osteoarthritis; the obesity indication is the regulatory path
• Standard OA treatment (exercise, PT, analgesics, intra-articular injections, surgery if needed) remains the framework; GLP-1 enters for obesity-related OA
• Effects on structural disease progression (cartilage, joint imaging) are not established in humans

Direct answer

The STEP 9 trial showed semaglutide 2.4 mg weekly produced meaningful reductions in knee osteoarthritis pain and improvements in function in adults with obesity (BMI 30+) and moderate-to-severe knee OA. The benefit is mostly weight-mediated; reducing body weight substantially reduces mechanical load on the knee. No GLP-1 medication is FDA-approved specifically for OA. The treatment indication remains obesity, with knee OA improvement as a secondary benefit. Standard OA care (exercise, physical therapy, analgesics, intra-articular injections, and surgery when needed) continues alongside GLP-1 treatment.

Table of contents

1. The obesity-OA mechanical link
2. STEP 9 trial design and outcomes
3. The 4:1 joint loading rule
4. Pain versus structure: what the trial measured
5. Other joints, other questions
6. GLP-1 alongside standard OA treatment
7. The joint replacement question
8. Anti-inflammatory effects: a smaller secondary mechanism
9. What patients experience
10. The contrary view: weight isn't everything
11. Decision framework
12. FAQ
13. Sources

The obesity-OA mechanical link

Knee osteoarthritis affects approximately 14 million Americans. Obesity is the most consistent modifiable risk factor. The Framingham OA study, Multicenter Osteoarthritis Study (MOST), and Osteoarthritis Initiative (OAI) all show strong associations between BMI and incident and progressive knee OA.

The mechanism is partly mechanical:

• Higher body weight increases joint loading during weight-bearing activities
• Repetitive loading drives cartilage wear over time
• Excess weight changes joint biomechanics, altering gait and load distribution
• Larger fat depots produce more inflammatory cytokines (leptin, TNF-alpha, IL-6) that affect joint tissues systemically

The mechanical contribution is largest for knees and hips (weight-bearing). Hand OA is less weight-mediated, suggesting the inflammatory pathway also matters but is secondary in load-bearing joints.

Pre-GLP-1 evidence already showed weight loss reduces OA symptoms. The Look AHEAD trial in diabetic patients and the IDEA trial (Messier et al., 2013) specifically in obese OA patients both demonstrated that lifestyle-driven weight loss reduces knee pain and improves function. The question for STEP 9 was whether pharmacotherapy-driven weight loss would produce similar or larger benefits.

STEP 9 trial design and outcomes

STEP 9 was the dedicated obesity-knee-OA trial of semaglutide. Bliddal et al. published results in 2024.

Design summary:

• Approximately 407 adults with BMI 30+ and knee osteoarthritis (Kellgren-Lawrence grade 2 or higher; moderate-to-severe pain)
• Semaglutide 2.4 mg weekly versus placebo
• 68 weeks treatment
• Co-primary endpoints: percent body weight change and WOMAC pain score change
• Key secondary endpoints: WOMAC function, WOMAC stiffness, IWQOL-Lite physical function score

Approximate results:

Outcome at 68 weeks	Semaglutide	Placebo
Body weight change	~ -13.7%	~ -3.2%
WOMAC pain score change (0-100 scale, lower = better)	~ -42 points	~ -28 points
WOMAC function score improvement	Significantly better than placebo	Baseline
IWQOL-Lite physical function	Significantly improved	Smaller change
Patient global assessment	Improved	Improved less

Both co-primary endpoints met significance. The pain reduction (~14 point difference between groups) is clinically meaningful per established minimum clinically important difference thresholds for WOMAC.

The placebo arm also improved, which is common in OA trials due to attention effects, lifestyle counseling, and natural fluctuation. The semaglutide effect was on top of substantial placebo improvement.

The 4:1 joint loading rule

The biomechanical rationale for weight-loss-driven OA benefit comes down to joint loading mathematics. During walking, knee joint forces are approximately 3-4 times body weight per leg.

For every pound of body weight lost:

• Walking knee load decreases approximately 4 pounds per step
• Stair climbing knee load decreases approximately 6 pounds per step
• Cumulative daily knee load decreases substantially

For a 200-pound patient who loses 14% body weight (28 pounds, a STEP 9-typical loss), daily knee loading decreases by tens of thousands of pounds across all weight-bearing activities. The reduction in mechanical stress allows inflamed tissues to recover and reduces pain signaling.

This explains why the pain improvement is reasonably proportional to weight loss magnitude, and why patients who lose more typically report more pain reduction.

Pain versus structure: what the trial measured

STEP 9 measured pain and function, not structural disease progression on imaging.

The structural picture in OA includes:

• Cartilage thickness and integrity
• Subchondral bone marrow lesions
• Synovitis
• Joint space narrowing
• Osteophyte formation

Whether weight loss or GLP-1 treatment reverses these structural changes is less clear. Some studies suggest cartilage thickness can stabilize or modestly improve with substantial weight loss, but reversing established structural damage is difficult for any intervention.

For most patients, pain and function improvement is what matters in daily life. Structural progression matters for long-term prognosis and surgical planning. STEP 9 addressed the former; the latter remains a research question.

Other joints, other questions

STEP 9 focused on knee OA. Other joints have less specific data:

• Hip OA. Also strongly weight-mediated. Biological plausibility for GLP-1 benefit is high. Trial-specific data are limited; general weight-loss research supports symptom improvement in obese hip OA.
• Hand OA. Less weight-mediated. GLP-1 effect on hand OA is minimal in expected mechanism terms. Anti-inflammatory contribution could theoretically help, but evidence is essentially absent.
• Spine OA / disc disease. Mixed mechanical and inflammatory drivers. Weight loss helps lumbar mechanics; specific GLP-1 trials in spine pain are limited.
• Ankle and foot OA. Weight-bearing joints, weight loss should help mechanically. Less common as a primary OA target.

For patients with multifocal OA, the knee benefit is most established, but generalizing to other weight-bearing joints is biologically reasonable.

GLP-1 alongside standard OA treatment

Standard OA treatment per ACR and OARSI guidelines:

• Exercise (aerobic, strengthening, neuromuscular)
• Physical therapy
• Weight management
• Topical NSAIDs (often preferred over oral due to better safety profile)
• Oral NSAIDs (with GI and CV risk consideration)
• Acetaminophen (limited efficacy)
• Intra-articular corticosteroids (short-term use)
• Hyaluronic acid injections (controversial; reduced enthusiasm in recent guidelines)
• Tramadol or duloxetine for refractory cases
• Joint replacement for end-stage disease

GLP-1 medications enter as a weight-management option that produces OA-relevant secondary benefit. They do not replace exercise, PT, or standard analgesics. They complement them by addressing the obesity component aggressively.

Important: muscle preservation matters during GLP-1 weight loss. Lean mass loss can compromise joint stability and protective musculature. Resistance training is particularly important for OA patients on GLP-1.

The joint replacement question

Joint replacement surgery (total knee arthroplasty, total hip arthroplasty) is the definitive treatment for end-stage OA. Obesity complicates surgery:

• Higher surgical risk (wound complications, infection, anesthesia challenges)
• Higher revision rates over time
• Some surgeons require BMI below a threshold (often 40, sometimes 35) before scheduling elective joint replacement

GLP-1 medications create new options:

• Patients above surgical BMI thresholds may reach eligibility through weight loss
• Patients with marginal OA severity may delay or avoid surgery through pain reduction
• Post-operative recovery may improve with continued weight management

STEP 9 did not measure surgery rates, but observational data and clinical experience suggest meaningful weight loss reduces near-term need for joint replacement in some patients.

The timing question matters: GLP-1 weight loss takes 6-18 months. For patients with severe symptoms and immediate quality-of-life concerns, surgery may be appropriate without waiting for medical weight loss. For patients with moderate symptoms and elevated BMI, a trial of GLP-1 medication before surgery is reasonable.

Anti-inflammatory effects: a smaller secondary mechanism

Beyond mechanical unloading, GLP-1 medications may contribute to OA improvement through anti-inflammatory effects:

• Reduced systemic inflammatory markers (CRP, IL-6, TNF-alpha)
• Lower leptin levels (leptin promotes joint inflammation)
• Possible direct effects on synovial fluid composition

The contribution of these effects to OA symptom improvement is smaller than the mechanical contribution, but not zero. The exact attribution is difficult to isolate from weight effects in clinical trials.

For OA phenotypes with strong inflammatory components (some elderly patients with multifocal disease), the anti-inflammatory mechanism may be more relevant. For mechanical-load-dominant OA in obese patients, the unloading effect dominates.

What patients experience

Common patient reports during GLP-1 treatment for obesity-related OA:

• Early improvement in stiffness and morning pain, often before substantial weight loss
• Most prominent pain reduction at months 4-9 once 8-12% body weight is lost
• Improved walking tolerance and stair climbing
• Better sleep due to reduced nighttime pain
• Reduced reliance on analgesics
• Function and pain plateau approximately when weight plateaus

The early improvement before substantial weight loss is interesting. It may reflect anti-inflammatory effects, reduced inflammatory cytokine production from rapidly mobilized fat depots, or placebo response. Most patients experience the largest benefit after sustained weight loss.

The contrary view: weight isn't everything

Argument 1: Some patients don't respond. A subset of patients with knee OA do not improve despite substantial weight loss. This may reflect advanced structural disease, alternative pain mechanisms (central sensitization, neuropathic pain), or non-OA contributors (meniscal damage, ligament instability) that GLP-1 cannot address.

Argument 2: Pain in OA is multifactorial. Cartilage damage does not correlate linearly with pain. Some patients have severe radiographic OA with minimal symptoms; others have mild radiographic findings with severe pain. Weight loss addresses mechanical load but not necessarily the full pain picture.

Argument 3: Lean mass loss during GLP-1 is a concern. Quadriceps strength is important for knee joint stability. Aggressive GLP-1 weight loss without resistance training can reduce protective musculature, potentially worsening function despite weight loss.

Argument 4: Existing OA treatments are underused. Exercise and physical therapy are first-line, evidence-based, and underprescribed. Promoting GLP-1 as an OA intervention may distract from broader use of established options.

Argument 5: Cost-effectiveness varies. For a patient near surgical BMI threshold who can avoid joint replacement, GLP-1 is highly cost-effective. For a patient with mild OA and modest weight loss potential, the cost-benefit picture is less clear.

Decision framework

If you have knee OA and BMI 30+: Discuss GLP-1 with your clinician. Coverage is typically through the obesity indication. Pair with exercise, PT, and standard analgesics.

If you have knee OA and BMI 27-30 with comorbidities: Obesity-with-comorbidity coverage path may apply. The OA itself is sometimes accepted as the comorbidity in some plans.

If you have knee OA and normal weight: GLP-1 is not appropriate. Standard OA treatment without weight-targeted pharmacotherapy.

If you are considering joint replacement and obese: Discuss whether 6-12 months of GLP-1 weight loss before surgery is appropriate. Some surgeons require this; others prefer to operate sooner. The decision is individualized.

If you have multifocal OA (knee, hip, hand): Weight loss helps the weight-bearing joints most. Hand OA benefit is theoretical.

If you have severe OA pain and rapid relief is the priority: GLP-1 takes months to produce benefit. For immediate relief, standard analgesics, intra-articular injections, or surgical referral may be more appropriate. GLP-1 can be added for longer-term improvement.

FAQ

Do GLP-1 medications help osteoarthritis?

Yes, in obesity-related knee OA. STEP 9 showed semaglutide reduced pain and improved function. The benefit is mostly weight-mediated.

What did STEP 9 show?

14% weight loss with semaglutide vs 3% placebo. Pain reduction larger on semaglutide. Function and quality of life improved.

Is it just weight loss doing the work?

Mostly. Mechanical unloading is the dominant mechanism. Anti-inflammatory effects contribute smaller benefit.

Should I take GLP-1 if I have knee OA but normal weight?

Probably not. STEP 9 enrolled BMI 30+. Benefit is tied to substantial weight loss.

Will GLP-1 prevent knee replacement?

Possibly in some patients. Substantial weight loss may delay or prevent surgery. STEP 9 did not measure surgery rates directly.

Does GLP-1 reverse cartilage damage?

Not established in humans. Pain and function improve; structural reversal is uncertain.

What about hip OA?

Less direct evidence but similar mechanism (weight-bearing joint). Reasonable to expect benefit, though not formally tested in STEP 9-equivalent trials.

Should I keep doing PT and exercise?

Yes. Exercise and PT remain first-line OA treatment. Resistance training is particularly important during GLP-1 weight loss to preserve muscle.

How long until OA pain improves?

Some early improvement at weeks 4-12; substantial reduction at months 4-9 once weight loss accrues; plateau around month 12-18.

What if I have severe OA?

GLP-1 may help reduce surgical risk via weight loss. For end-stage symptomatic disease, joint replacement may be appropriate without delay.

What about other GLP-1 medications?

STEP 9 was specifically semaglutide. Tirzepatide likely produces similar or larger benefit via more substantial weight loss, but dedicated tirzepatide OA trial data are limited.

Will insurance cover it for OA?

Not typically as an OA-specific indication. Coverage flows through the obesity indication or obesity-with-comorbidity (where OA can serve as the comorbidity for the BMI 27+ tier in some plans).

Related guides

• Why GLP-1 Medications Cause Headaches When Lying Down: The Intracranial Pressure Connection and a Working Protocol
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• Why GLP-1 Medications Create a Perfect Storm for Both Kidney Stones and Constipation (and the Prevention Protocol That Addresses Both)
• Getting Pregnant on Ozempic: Why GLP-1 Medications Increase Pregnancy Risk and What to Do If You Conceive
• GLP-1 Medications for PCOS: What the Evidence Actually Shows
• GLP-1 Medications for MASH and Fatty Liver: The Evidence Map

Sources

1. Bliddal H et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (STEP 9). 2024.
2. Messier SP et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes (IDEA trial). JAMA. 2013.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
5. Kolasinski SL et al. 2019 American College of Rheumatology / Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. 2020.
6. Bannuru RR et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019.
7. Felson DT et al. The effects of impaired joint position sense on the development and progression of pain and structural damage in knee osteoarthritis. Arthritis Care & Research. 2009.
8. Christensen R et al. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases. 2007.
9. Messier SP et al. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis and Rheumatism. 2005.
10. Centers for Disease Control and Prevention. Arthritis Data and Statistics. 2024 update.
11. FDA Drug Label. Wegovy (semaglutide) Prescribing Information. Updated 2024.
12. FDA Drug Label. Zepbound (tirzepatide) Prescribing Information. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational content. Osteoarthritis management is a coordinated effort across primary care, rheumatology, orthopedics, and physical therapy. This article is not a substitute for personalized clinical evaluation. Treatment of OA should be individualized to your specific joint involvement, severity, and comorbidities.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved and have not been studied specifically for osteoarthritis. Compounded medications are prepared by state-licensed 503A compounding pharmacies pursuant to individual prescriptions and are not interchangeable with brand-name products.

Results Disclaimer. STEP 9 described average outcomes in the trial population. Individual response in OA depends on disease severity, structural status, alternative pain contributors, exercise adherence, and other factors. Pain and function improvement does not necessarily reflect structural disease change.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.